Fluticasone propionate
- Generic Name
- Fluticasone propionate
- Brand Names
- Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
- Drug Type
- Small Molecule
- Chemical Formula
- C25H31F3O5S
- CAS Number
- 80474-14-2
- Unique Ingredient Identifier
- O2GMZ0LF5W
- Background
Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.
- Indication
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
- Associated Conditions
- Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
- Associated Therapies
- -
The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- JHSPH Center for Clinical Trials
- Target Recruit Count
- 500
- Registration Number
- NCT00156819
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
🇺🇸New York Medical College, Valhalla, New York, United States
🇺🇸University of Miami (and University of South Florida in Tampa), Miami, Florida, United States
Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 200
- Registration Number
- NCT00158834
- Locations
- 🇳🇱
GSK Investigational Site, Zwolle, Netherlands
Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 154
- Registration Number
- NCT00127166
Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis
- First Posted Date
- 2005-07-25
- Last Posted Date
- 2008-01-16
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 30
- Registration Number
- NCT00123656
- Locations
- 🇺🇸
University of Utah HSC, Salt Lake City, Utah, United States
Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial
- Conditions
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2006-05-09
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 250
- Registration Number
- NCT00120978
- Locations
- 🇨🇦
Wetaskiwin Lung Laboratory, Wetaskiwin, Alberta, Canada
🇨🇦Lion's Gate Hospital, North Vancouver, British Columbia, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 102
- Registration Number
- NCT00119015
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 248
- Registration Number
- NCT00118716
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
- First Posted Date
- 2004-03-22
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 628
- Registration Number
- NCT00079937
- Locations
- 🇺🇸
Clinical Research Institute of Southern Oregon, Medford, Oregon, United States
🇺🇸Family Allergy and Asthma Center, PC, Atlanta, Georgia, United States
🇺🇸West Penn Allegheny General Health System, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.